Arena Capital Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Arena Capital Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,287	Closed	-$43K	–	169
2022 Q3	$43K	Hold	4,287	–	–	0.01%	130
2022 Q2	$42K	Hold	4,287	–	–	0.01%	161
2022 Q1	$42K	Hold	4,287	–	–	0.01%	220
2021 Q4	$42K	Hold	4,287	–	–	﹤0.01%	318
2021 Q3	$43K	Buy	4,287 +105	+3%	+$1.03K	﹤0.01%	337
2021 Q2	$41K	Buy	+4,182	New	+$41K	﹤0.01%	352

Other funds holding TLSI

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

DFCM

Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Arena Capital Advisors's TLSI Position: Q4 2022 in Review

Arena Capital Advisors sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 4,287 shares — an estimated $43K sold.

Arena Capital Advisors first reported a position in TLSI in Q2 2021 and held it in 6 quarters. The position peaked at $43K in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

Arena Capital Advisors reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
Arena Capital Advisors sold 4,287 TriSalus Life Sciences shares in Q4 2022, an estimated $43K.
Arena Capital Advisors first reported a position in TriSalus Life Sciences in Q2 2021 and held it in 6 quarters.
Arena Capital Advisors's TriSalus Life Sciences position peaked at $43K in Q3 2022.
9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Arena Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.